HIV / AIDS in the News

Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma

 

Single daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens - Medical Xpress

 

New single-pill HIV therapy promises boost for long-term virus survivors - Financial Times

 

A single once-daily pill combining two antiretrovirals simplifies HIV treatment, as demonstrated by a phase 3 trial - Science Media Centre España

 

US funding freeze linked to HIV care disruptions in 32 countries, study finds - Medical Xpress

 

How can PrEP use among Black people be improved? - Advocate.com

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's

 

Two-drug HIV pill from Merck rivals standard treatment in trials - Stock Titan

 

Age, HIV, and Metabolic Syndrome Together Tied to Cognitive Impairment Risk - MedPage Today

 

Tacoma City Council approves funding for HIV, STI self-testing for LGBTQ+ youth - KOMO

 

Funding cuts are devastating Black HIV prevention work. But activists say pressure is working. - LGBTQ Nation

 

DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV - Clinical Trials Arena

 

Press Telecon @ 12:15 pm ET: FL Health Dept. Signs Death Warrant for 16,000 AIDS Drug Recipients - AIDS Healthcare Foundation

 

Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals - Aidsmap

 

Single-Dose Dolutegravir Safe in Kids With HIV Receiving Preventive TB Treatment - MedPage Today

 

New Insights Into Hypertension and MACE Reduction in HIV: Steven Grinspoon, MD - AJMC

 

Traditional Chinese Medicine Shows Promise for HIV Comorbidities - Docwire News

 

Balazs Lab Study Reveals HIV Escapes Antibody Therapy Through Predictable Paths, and Blocking Them Can Achieve Sustained Viral Suppression - Ragon Institute